⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for asciminib

Every month we try and update this database with for asciminib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Frontline Asciminib Combination in Chronic Phase CMLNCT03906292
Chronic Myeloid...
Imatinib
Nilotinib 300 m...
Dasatinib
Asciminib
18 Years - University of Jena
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsNCT03106779
Chronic Myeloge...
Asciminib
Bosutinib
18 Years - Novartis
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase InhibitorNCT04216563
Philadelphia Ch...
Asciminib
18 Years - M.D. Anderson Cancer Center
Special Drug Use-results Surveillance of Scemblix TabletsNCT05421091
Chronic Myeloid...
Asciminib
- 99 YearsNovartis
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsNCT04795427
Leukemia, Chron...
asciminib
best available ...
18 Years - Novartis
Asciminib Roll-over StudyNCT04877522
Chronic Myeloge...
Leukemia, Myelo...
Asciminib singl...
Asciminib
Imatinib
Nilotinib
Bosutinib
Dasatinib
18 Years - Novartis
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseNCT05143840
Chronic Myeloid...
Adult CML
Leukemia, Myelo...
Leukemia,Myeloi...
Asciminib
Ascimininb + Ni...
Asciminib + Ima...
Asciminib + Das...
18 Years - Augusta University
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid LeukemiaNCT06368414
Chronic Myeloid...
Asciminib
19 Years - Korean Society of Hematology
Special Drug Use-results Surveillance of Scemblix TabletsNCT05421091
Chronic Myeloid...
Asciminib
- 99 YearsNovartis
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)NCT03578367
CML
Chronic Myeloge...
Leukemia, Myelo...
Hematologic Dis...
Asciminib add-o...
Imatinib
Nilotinib
Asciminib singl...
18 Years - Novartis
Asciminib RMP StudyNCT05943522
Chronic Myeloid...
Asciminib
18 Years - Novartis
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNCT06308588
Philadelphia Ch...
Acute Lymphobla...
Blinatumomab
Asciminib
18 Years - M.D. Anderson Cancer Center
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)NCT03578367
CML
Chronic Myeloge...
Leukemia, Myelo...
Hematologic Dis...
Asciminib add-o...
Imatinib
Nilotinib
Asciminib singl...
18 Years - Novartis
Asciminib RMP StudyNCT05943522
Chronic Myeloid...
Asciminib
18 Years - Novartis
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNCT04971226
Chronic Myeloid...
Imatinib
Nilotinib
Bosutinib
Dasatinib
Asciminib
18 Years - Novartis
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I MutationNCT06427811
Philadelphia Ch...
Asciminib
18 Years - Novartis
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseNCT05143840
Chronic Myeloid...
Adult CML
Leukemia, Myelo...
Leukemia,Myeloi...
Asciminib
Ascimininb + Ni...
Asciminib + Ima...
Asciminib + Das...
18 Years - Augusta University
Frontline Asciminib Combination in Chronic Phase CMLNCT03906292
Chronic Myeloid...
Imatinib
Nilotinib 300 m...
Dasatinib
Asciminib
18 Years - University of Jena
Managed Access Programs for ABL001, AsciminibNCT04360005
Chronic Myeloid...
Asciminib
18 Years - 99 YearsNovartis
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase InhibitorNCT04216563
Philadelphia Ch...
Asciminib
18 Years - M.D. Anderson Cancer Center
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid LeukemiaNCT06368414
Chronic Myeloid...
Asciminib
19 Years - Korean Society of Hematology
Asciminib Roll-over StudyNCT04877522
Chronic Myeloge...
Leukemia, Myelo...
Asciminib singl...
Asciminib
Imatinib
Nilotinib
Bosutinib
Dasatinib
18 Years - Novartis
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLNCT02081378
Chronic Myeloge...
Philadelphia Ch...
Asciminib (ABL0...
Nilotinib
Imatinib
Dasatinib
18 Years - Novartis
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in FranceNCT06092879
Chronic Myeloid...
Asciminib
18 Years - 99 YearsNovartis
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsNCT03106779
Chronic Myeloge...
Asciminib
Bosutinib
18 Years - Novartis
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: